Haematopoietic stem cell transplantation (HSCT), oncolytic viruses, checkpoint inhibitors and chemotherapeutic agents in combination with CAR‐T cells have shown great potential as several new therapeutic strategies in the treatment of human haematological malignancies.CD33 CAR‐T cells in combination with Allo‐HSCT have shown less haematopoietic toxicity in patients with CD33+ AML.CD33 CAR‐T cells eliminated CD33+ primitive cells without effect on CD33‐haematopoietic stem cells (HSPC).121, 122. This evidence concerns the gene CD33 and acute myeloid leukemia.